Elite Journal of Haematology. Volume 2 issue 3(2024), Pp. 136-147
https://epjournals.com/journals/EJH

Balancing Act: Glycemic Control and Hematological Considerations in Sickle Cell Diabetes

*Emmanuel Ifeanyi Obeagu[1], Elham Ali Ibrahim Elamin[2] and Getrude Uzoma Obeagu[3]

[1]Department of Medical Laboratory Science, Kampala International University, Uganda

[2]Hematology and Immunohematology, Faculty of Medical Laboratory Sciences, University of ElImam EI Mahdi, Sudan

[3]School of Nursing Science, Kampala International University, Uganda

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

Sickle cell disease (SCD) and diabetes mellitus (DM) are two chronic conditions with distinct pathophysiological mechanisms and clinical implications. However, the coexistence of these conditions, known as sickle cell diabetes, presents a complex management challenge characterized by the need to balance glycemic control with hematological considerations. This review explores the intricate interplay between SCD and DM, highlighting the bidirectional relationship between these conditions and their impact on patient outcomes. Specifically, the review examines the effects of hyperglycemia and hypoglycemia on hematological parameters, emphasizing the potential exacerbation of SCD-related complications. Furthermore, it discusses management strategies aimed at optimizing glycemic control while minimizing hematological risks in patients with sickle cell diabetes, emphasizing the importance of an interdisciplinary approach. By elucidating the pathophysiological links between SCD and DM and providing insights into effective management strategies, this review aims to enhance understanding and guide clinical practice in addressing this challenging comorbidity.

Keywords*: Sickle Cell Disease, Diabetes Mellitus, Glycemic Control, Hematological Complications, Hyperglycemia, Hypoglycemia, Management Strategies*

Citation: Obeagu EI, Elamin EAI Obeagu GU. Balancing Act: Glycemic Control and Hematological Considerations in Sickle Cell Diabetes. *Elite Journal of Haematology, 2024; 2(3):* 136-147

Introduction

Sickle cell disease (SCD) and diabetes mellitus (DM) are chronic conditions that individually pose significant health challenges worldwide. SCD, a genetic disorder characterized by the presence of abnormal hemoglobin (HbS), predisposes individuals to vaso-occlusive crises, hemolytic anemia, and organ damage. Conversely, DM, a metabolic disorder marked by insulin resistance and/or inadequate insulin production, contributes to various macrovascular and microvascular complications. Despite their distinct etiologies, these conditions frequently coexist, particularly in populations with a high prevalence of both SCD and DM. The convergence of SCD and DM, termed sickle cell diabetes, presents a multifaceted clinical scenario characterized by overlapping pathophysiological mechanisms and unique management considerations. The pathophysiological links between SCD and DM underscore the complexity of sickle cell diabetes. SCD-induced inflammation, oxidative stress, and endothelial dysfunction contribute to β-cell dysfunction and insulin resistance, predisposing individuals with SCD to the development of DM. Conversely, hyperglycemia and insulin resistance in DM may exacerbate the underlying hematological abnormalities in SCD, including increased red blood cell sickling, endothelial activation, and vaso-occlusive events. This bidirectional relationship between SCD and DM necessitates a comprehensive understanding of their interplay and its implications for patient management.[1-31]

The impact of glycemic control on hematological parameters is a critical consideration in sickle cell diabetes. Hyperglycemia has been associated with increased oxidative stress, inflammation, and endothelial dysfunction, all of which may contribute to the pathogenesis of SCD-related complications, including vaso-occlusive crises and acute chest syndrome. Conversely, hypoglycemia can precipitate hemolytic crises, exacerbate anemia, and worsen tissue ischemia in individuals with SCD. Thus, achieving optimal glycemic control while mitigating the risk of hematological complications is paramount in the management of sickle cell diabetes. Management strategies for sickle cell diabetes require a multidisciplinary approach that addresses both glycemic control and hematological considerations. Lifestyle modifications, including dietary changes, regular physical activity, and smoking cessation, are fundamental to diabetes management and may also have beneficial effects on SCD-related complications. Pharmacological interventions, such as insulin therapy or oral hypoglycemic agents, should be tailored to individual patient needs, considering factors such as disease severity, comorbidities, and medication interactions. Moreover, proactive measures to prevent vaso-occlusive crises, optimize hematological parameters, and manage pain are essential components of comprehensive care for individuals with sickle cell diabetes.[32-52]

Pathophysiological Links between SCD and Diabetes

The pathophysiological links between sickle cell disease (SCD) and diabetes mellitus (DM) are multifaceted, involving intricate interactions between inflammatory, oxidative, and endothelial

dysfunction pathways. While these conditions arise from distinct genetic and metabolic abnormalities, their coexistence, known as sickle cell diabetes, underscores shared pathophysiological mechanisms that contribute to their complex interplay. SCD is characterized by chronic inflammation, driven by the activation of leukocytes, platelets, and endothelial cells in response to hemolysis, tissue ischemia, and vaso-occlusive events. This inflammatory milieu promotes the secretion of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), which contribute to insulin resistance and β-cell dysfunction in DM. Conversely, hyperglycemia in DM exacerbates inflammation by enhancing the production of reactive oxygen species (ROS), activating nuclear factor-kappa B (NF-κB) signaling, and amplifying inflammatory responses. The synergistic effects of chronic inflammation in SCD and DM create a pro-inflammatory environment that potentiates the development and progression of both conditions.[53-65]

Oxidative stress plays a central role in the pathophysiology of both SCD and DM, contributing to endothelial dysfunction, tissue damage, and organ dysfunction. In SCD, hemolysis and ischemia-reperfusion injury led to the release of free hemoglobin and heme, which promote the generation of reactive oxygen species (ROS) and oxidative damage to vascular endothelium. Similarly, hyperglycemia in DM results in increased production of ROS via multiple pathways, including glucose autoxidation, mitochondrial dysfunction, and activation of NADPH oxidase. The resultant oxidative stress impairs insulin signaling, exacerbates endothelial dysfunction, and contributes to microvascular and macrovascular complications in both SCD and DM. Endothelial dysfunction is a hallmark feature of both SCD and DM, characterized by impaired nitric oxide (NO) bioavailability, increased expression of adhesion molecules, and enhanced platelet activation. In SCD, chronic hemolysis, inflammation, and vaso-occlusive events disrupt endothelial integrity, leading to vasoconstriction, thrombosis, and tissue ischemia. Similarly, hyperglycemia in DM induces endothelial dysfunction through multiple mechanisms, including reduced NO production, increased endothelin-1 expression, and enhanced oxidative stress. The convergence of endothelial dysfunction in SCD and DM contributes to microvascular complications, such as nephropathy, retinopathy, and neuropathy, and macrovascular complications, including stroke, myocardial infarction, and peripheral artery disease. The unique hemoglobin abnormalities in SCD and DM contribute to their pathophysiological overlap. In DM, chronic hyperglycemia leads to non-enzymatic glycation of hemoglobin, forming hemoglobin A1c (HbA1c), which reflects long-term glycemic control. Similarly, in SCD, sickle hemoglobin (HbS) polymerization occurs in response to deoxygenation, leading to erythrocyte sickling and vaso-occlusive events. The glycation of hemoglobin in DM and the polymerization of sickle hemoglobin in SCD contribute to tissue hypoxia, oxidative stress, and endothelial dysfunction, further exacerbating the pathophysiological links between these conditions.[66-67]

Impact of Hyperglycemia and Hypoglycemia on Hematological Parameters

Citation: Obeagu EI, Elamin EAI Obeagu GU. Balancing Act: Glycemic Control and Hematological Considerations in Sickle Cell Diabetes. *Elite Journal of Haematology, 2024; 2(3):* 136-147

The impact of hyperglycemia and hypoglycemia on hematological parameters is of paramount importance, particularly in individuals with sickle cell disease (SCD) and concomitant diabetes mellitus (DM). Both hyperglycemia and hypoglycemia can exert significant effects on the hematological profile, exacerbating the underlying pathophysiology of SCD and potentially precipitating acute complications. Hyperglycemia, characterized by elevated blood glucose levels, is associated with increased oxidative stress, inflammation, and endothelial dysfunction.[68-69] In individuals with SCD, hyperglycemia can exacerbate the underlying pro-inflammatory state and endothelial activation, promoting the adhesion of sickled red blood cells to the vascular endothelium. This adhesive interaction further contributes to vaso-occlusive events, tissue ischemia, and end-organ damage characteristic of SCD. Moreover, hyperglycemia may impair red blood cell deformability and increase blood viscosity, further compromising blood flow and exacerbating vaso-occlusion. Conversely, hypoglycemia, characterized by low blood glucose levels, can precipitate hemolytic crises and exacerbate anemia in individuals with SCD. Hypoglycemia triggers the release of stress hormones, including epinephrine and cortisol, which stimulate red blood cell sickling and increase hemolysis. The resultant increase in free hemoglobin levels and hemolytic rate can further worsen anemia, leading to tissue hypoxia and organ damage. Moreover, hypoglycemia-induced vasoconstriction and impaired tissue perfusion may exacerbate tissue ischemia and predispose individuals with SCD to vaso-occlusive complications.

Hyperglycemia and hypoglycemia can also impact other hematological parameters beyond red blood cells. Hyperglycemia is associated with platelet hyperreactivity, increased coagulation activity, and endothelial dysfunction, predisposing individuals to thrombotic events and microvascular complications. In contrast, hypoglycemia-induced release of stress hormones may activate the coagulation cascade, leading to platelet aggregation and thrombus formation. Additionally, glucose fluctuations can affect leukocyte function and inflammatory responses, further contributing to the pathogenesis of SCD-related complications. The impact of hyperglycemia and hypoglycemia on hematological parameters highlights the importance of glycemic control in individuals with SCD and DM. Achieving and maintaining euglycemia, within a target range, is essential for minimizing the risk of acute complications and optimizing long-term outcomes. Tailored management strategies, including lifestyle modifications, pharmacological interventions, and regular monitoring of blood glucose levels, are necessary to achieve glycemic targets while mitigating the risk of hematological complications in this vulnerable population.[69-70]

Management Strategies

Management strategies for individuals with sickle cell diabetes, aiming to optimize glycemic control while minimizing hematological complications, require a comprehensive and multidisciplinary approach. These strategies encompass lifestyle modifications, pharmacological interventions, and proactive measures to address both diabetes-related and sickle cell-related complications. Lifestyle modifications play a fundamental role in the management of sickle cell

diabetes. Patients should be encouraged to adopt healthy dietary habits, focusing on a balanced diet rich in fruits, vegetables, whole grains, and lean proteins. Monitoring carbohydrate intake and avoiding foods with high glycemic index can help regulate blood glucose levels. Regular physical activity is also important for improving insulin sensitivity and overall health. However, individuals with SCD should engage in low-impact exercises to minimize the risk of vaso-occlusive events.[71-73]

Pharmacological interventions for glycemic control in sickle cell diabetes may include insulin therapy or oral hypoglycemic agents. Insulin therapy is often preferred in individuals with more severe forms of diabetes or those requiring tighter glycemic control. Long-acting insulin formulations, such as basal insulin analogs, may be used to provide basal coverage, while short-acting insulin or rapid-acting insulin analogs can be administered before meals to control postprandial glucose excursions. Alternatively, oral hypoglycemic agents, such as metformin or sulfonylureas, may be considered in patients with less severe diabetes or those who are unable to tolerate insulin therapy. Regular monitoring of blood glucose levels is essential for assessing glycemic control and adjusting treatment regimens as needed. Patients with sickle cell diabetes should undergo comprehensive medical evaluations, including assessments of hematological parameters, renal function, and cardiovascular risk factors. Individualized care plans should consider patient-specific factors, including disease severity, comorbidities, medication interactions, and psychosocial factors. Close collaboration between hematologists, endocrinologists, primary care physicians, and other healthcare providers is crucial for coordinating care and optimizing outcomes. Proactive measures to prevent vaso-occlusive crises and manage sickle cell-related complications are essential components of comprehensive care for individuals with sickle cell diabetes. Hydroxyurea therapy, a disease-modifying agent that increases fetal hemoglobin levels and reduces the frequency of vaso-occlusive events, may be beneficial in select patients with SCD. Additionally, transfusion therapy, pain management strategies, and prophylactic antibiotics may be indicated to prevent complications such as acute chest syndrome, infections, and stroke. Regular monitoring of hematological parameters, including hemoglobin levels, reticulocyte counts, and markers of hemolysis, can help guide treatment decisions and assess response to therapy. Patient education and support are integral components of successful management strategies for sickle cell diabetes. Patients should receive comprehensive education about their conditions, including the importance of glycemic control, recognition of symptoms of hyperglycemia and hypoglycemia, and self-management skills, such as blood glucose monitoring and insulin administration. Additionally, patients should be empowered to advocate for their health, communicate effectively with healthcare providers, and access resources for psychosocial support and disease management.[71-74]

Conclusion

Citation: Obeagu EI, Elamin EAI Obeagu GU. Balancing Act: Glycemic Control and Hematological Considerations in Sickle Cell Diabetes. *Elite Journal of Haematology, 2024; 2(3):* 136-147

The management of sickle cell diabetes presents a complex challenge that requires a comprehensive and multidisciplinary approach. The coexistence of sickle cell disease (SCD) and diabetes mellitus (DM) necessitates a delicate balance between glycemic control and hematological considerations to optimize patient outcomes. Management strategies for sickle cell diabetes should encompass lifestyle modifications, pharmacological interventions, and proactive measures to prevent acute complications. Lifestyle modifications, including dietary changes, regular physical activity, and smoking cessation, are essential for managing both diabetes and SCD-related complications. Pharmacological interventions, such as insulin therapy or oral hypoglycemic agents, should be individualized based on patient characteristics and monitored closely to achieve optimal glycemic control while minimizing the risk of hematological complications.

References

1. Yawn BP, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell KL, James AH, Jordan L, Lanzkron SM, Lottenberg R, Savage WJ, Tanabe PJ. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. Jama. 2014;312(10):1033-1048.
2. Pecker LH, Little J. Clinical manifestations of sickle cell disease across the lifespan. Sickle cell disease and hematopoietic stem cell transplantation. 2018:3-9.
3. Kavanagh PL, Fasipe TA, Wun T. Sickle cell disease: a review. Jama. 2022;328(1):57-68.
4. Kato GJ, Piel FB, Reid CD, Gaston MH, Ohene-Frempong K, Krishnamurti L, Smith WR, Panepinto JA, Weatherall DJ, Costa FF, Vichinsky EP. Sickle cell disease. Nature reviews Disease primers. 2018 ;4(1):1-22.
5. Ahmed S, Ibrahim U. The Roles of Acute and Chronic Marrow Dysfunctions in the Aetiology of Anaemia in Sickle Cell Disease: Pathogenesis and Management: Marrow dysfunction in SCD. Orient Journal of Medicine. 2024;36(3-4).
6. Obeagu EI, Ochei KC, Nwachukwu BN, Nchuma BO. Sickle cell anaemia: a review. Scholars Journal of Applied Medical Sciences. 2015;3(6B):224422-52.
7. Obeagu EI. Erythropoeitin in Sickle Cell Anaemia: A Review. International Journal of Research Studies in Medical and Health Sciences. 2020;5(2):22-28.
8. Obeagu EI. Sickle Cell Anaemia: Haemolysis and Anemia. Int. J. Curr. Res. Chem. Pharm. Sci. 2018;5(10):20-21.
9. Obeagu EI, Muhimbura E, Kagenderezo BP, Uwakwe OS, Nakyeyune S, Obeagu GU. An Update on Interferon Gamma and C Reactive Proteins in Sickle Cell Anaemia Crisis. J Biomed Sci. 2022;11(10):84.
10. Obeagu EI, Bunu UO, Obeagu GU, Habimana JB. Antioxidants in the management of sickle cell anaemia: an area to be exploited for the wellbeing of the patients. International Research in Medical and Health Sciences. 2023 Sep 11;6(4):12-17.

Citation: Obeagu EI, Elamin EAI Obeagu GU. Balancing Act: Glycemic Control and Hematological Considerations in Sickle Cell Diabetes. *Elite Journal of Haematology, 2024; 2(3):* 136-147

11. Obeagu EI, Ogunnaya FU, Obeagu GU, Ndidi AC. Sickle cell anaemia: a gestational enigma. European Journal of Biomedical and Pharmaceutical Sciences. 2023;10((9): 72-75
12. Obeagu EI. An update on micro RNA in sickle cell disease. Int J Adv Res Biol Sci. 2018; 5:157-8.
13. Obeagu EI, Babar Q. Covid-19 and Sickle Cell Anemia: Susceptibility and Severity. J. Clinical and Laboratory Research. 2021;3(5):2768-0487.
14. Obeagu EI. Depression in Sickle Cell Anemia: An Overlooked Battle. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(10):41-.
15. Obeagu EI, Obeagu GU. Evaluation of Hematological Parameters of Sickle Cell Anemia Patients with Osteomyelitis in A Tertiary Hospital in Enugu, Nigeria. Journal of Clinical and Laboratory Research.2023;6(1):2768-0487.
16. Obeagu EI, Dahir FS, Francisca U, Vandu C, Obeagu GU. Hyperthyroidism in sickle cell anaemia. Int. J. Adv. Res. Biol. Sci. 2023;10(3):81-89.
17. Obeagu EI, Obeagu GU, Akinleye CA, Igwe MC. Nosocomial infections in sickle cell anemia patients: Prevention through multi-disciplinary approach: A review. Medicine. 2023;102(48):e36462.
18. Njar VE, Ogunnaya FU, Obeagu EI. Knowledge And Prevalence of The Sickle Cell Trait Among Undergraduate Students Of The University Of Calabar. Prevalence.;5(100):0-5.
19. Swem CA, Ukaejiofo EO, Obeagu EI, Eluke B. Expression of micro RNA 144 in sickle cell disease. Int. J. Curr. Res. Med. Sci. 2018;4(3):26-32.
20. Obeagu EI, Nimo OM, Bunu UO, Ugwu OP, Alum EU. Anaemia in children under five years: African perspectives. Int. J. Curr. Res. Biol. Med. 2023;1:1-7.
21. Obeagu EI. Sickle cell anaemia: Historical perspective, Pathophysiology and Clinical manifestations. Int. J. Curr. Res. Chem. Pharm. Sci. 2018;5(11):13-15.
22. Ifediora AC, Obeagu EI, Akahara IC, Eguzouwa UP. Prevalence of urinary tract infection in diabetic patients attending Umuahia health care facilities. J Bio Innov. 2016;5(1):68-82. links/5ae45fdfaca272ba507eb3c3/PREVALENCE-OF-URINARY-TRACT-INFECTION-IN-DIABETIC-PATIENTS-ATTENDING-UMUAHIA-HEALTH-CARE-FACILITIES.pdf.
23. Ugwu OP, Alum EU, Okon MB, Aja PM, Obeagu EI, Onyeneke EC. Ethanol root extract and fractions of Sphenocentrum jollyanum abrogate hyperglycaemia and low body weight in streptozotocin-induced diabetic Wistar albino rats. RPS Pharmacy and Pharmacology Reports. 2023;2(2):rqad010.
24. Obeagu EI, Obeagu GU. Utilization of Antioxidants in the management of diabetes mellitus patients. J Diabetes Clin Prac. 2018;1(102):2. links/5b6c2dec92851ca65053b74e/Utilization-of-Antioxidants-in-the-Management-of-Diabetes-Mellitus.pdf.
25. Obeagu EI, Okoroiwu IL, Obeagu GU. Some haematological variables in insulin dependent diabetes mellitus patients in Imo state Nigeria. Int. J. Curr. Res. Chem. Pharm.

Citation: Obeagu EI, Elamin EAI Obeagu GU. Balancing Act: Glycemic Control and Hematological Considerations in Sickle Cell Diabetes. *Elite Journal of Haematology, 2024; 2(3):* 136-147

Sci. 2016;3(4):110-7. links/5ae4abee458515760ac07a13/Some-haematological-variables-in-insulin-dependent-diabetes-mellitus-patients-in-Imo-state-Nigeria.pdf.

26. Nwakuilite A, Nwanjo HU, Nwosu DC, Obeagu EI. Evaluation of some trace elements in streptozocin induced diabetic rats treated with Moringa oleifera leaf powder. WJPMR. 2020;6(12):15-8. links/5fcb587092851c00f8516430/EVALUATION-OF-SOME-TRACE-ELEMENTS-IN-STREPTOZOCIN-INDUCED-DIABETIC-RATS-TREATED-WITH-MORINGA-OLEIFERA-LEAF-POWDER.pdf.
27. Anyiam AF, Obeagu EI, Obi E, Omosigho PO, Irondi EA, Arinze-Anyiam OC, Asiyah MK. ABO blood groups and gestational diabetes among pregnant women attending University of Ilorin Teaching Hospital, Kwara State, Nigeria. International Journal of Research and Reports in Hematology. 2022;5(2):113-121.
28. Okafor CJ, Yusuf SA, Mahmoud SA, Salum SS, Vargas SC, Mathew AE, Obeagu EI, Shaib HK, Iddi HA, Moh'd MS, Abdulrahman WS. Effect of Gender and Risk Factors in Complications of Type 2 Diabetic Mellitus among Patients Attending Diabetic Clinic in Mnazi Mmoja Hospital, Zanzibar. Journal of Pharmaceutical Research International. 2021;33(29B):67-78.
29. Galano ES, Yusuf SA, Ogbonnia SO, Ogundahunsi OA, Obeagu EI, Chukwuani U, Okafor CJ, Obianagha NF. Effect of Extracts of Kigelia Africana Fruit and Sorghum Bicolor Stalk on the Biochemical Parameters of Alloxan-Induced Diabetic Rats. Journal of Pharmaceutical Research International. 2021;33(25B):86-97.
30. Kama SC, Obeagu EI, Alo MN, Ochei KC, Ezugwu UM, Odo M, Ikpeme M, Ukeekwe CO, Amaeze AA. Incidence of Urinary Tract Infection among Diabetic Patients in Abakaliki Metropolis. Journal of Pharmaceutical Research International. 2020 Nov 17;32(28):117-121.
31. Nwakulite A, Obeagu EI, Eze R, Vincent CC, Chukwurah EF, Okafor CJ, Ibekwe AM, Adike CN, Chukwuani U, Ifionu BI. Evaluation of Catalase and Manganese in Type 2 Diabetic Patients in University of Port Harcourt Teaching Hospital. Journal of Pharmaceutical Research International. 2021:40-45.
32. Nwakulite A, Obeagu EI, Nwanjo HU, Nwosu DC, Nnatuanya IN, Vincent CC, Amaechi CO, Ochiabu O, Barbara MT, Ibekwe AM, Okafor CJ. Studies on Pancreatic Gene Expression in Diabetic Rats Treated with Moringa oleifera Leaf. Journal of Pharmaceutical Research International. 2021;33(28A):78-86.
33. Nwosu DC, Nwanjo HU, Obeagu EI, Ugwu GU, Ofor IB, Okeke A, Ochei KC, Kanu SN, Okpara KE. Evaluation of Lipoprotein A and Lipid Tetrad Index Pattern in Diabetic Patients Attending Metabolic Clinic in The Federal Medical Centre, Owerri, Imo State. World Journal of Pharmacy and Pharmaceutical Sciences, 2015; 4 (3):126-140
34. Ezema GO, Omeh NY, Egbachukwu S, Agbo EC, Ikeyi AP, Obeagu EI. Evaluation of Biochemical Parameters of Patients with Type 2 Diabetes Mellitus Based on Age and Gender in Umuahia. Asian Journal of Dental and Health Sciences. 2023 Jun 15;3(2):32-36. http://ajdhs.com/index.php/journal/article/view/43.

Citation: Obeagu EI, Elamin EAI Obeagu GU. Balancing Act: Glycemic Control and Hematological Considerations in Sickle Cell Diabetes. *Elite Journal of Haematology, 2024; 2(3):* 136-147

35. Adu ME, Chukwuani U, Ezeoru V, Okafor CJ, Amaechi CO, Vincent CC, Obeagu GU, Eze R, Nnatuanya IN, Nwosu DC, Nwanjo HU. Studies on molecular docking of moringa oleifera leaf phytochemical constituents on alpha glucosidase, alpha amylase and dipeptidyl peptidase. Journal of Pharmaceutical Research International. 2021;33(28A):239-345.
36. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Obeagu EI. Plasma Level of Macromolecules and Mathematical Calculation of Potential Energy in Type 2 Diabetic Individuals at NAUTH, Nnewi, Nigeria. Journal of Pharmaceutical Research International. 2021;33(47B):242-248.
37. Nwakulite A, Obeagu EI, Eze R, Ugochi VE, Vincent CC, Okafor CJ, Chukwurah EF, Unaeze BC, Amaechi CO, Okwuanaso CB, Chukwuani U. Estimation of Serum Glutathione Peroxidase in Streptozotocin Induced Diabetic Rat Treated with Bitter Leaf Extract. Journal of Pharmaceutical Research International. 2021;33(30B):200-206.
38. Okoroiwu IL, Obeagu EI, San Miguel HG, Bote SA, Obeagu GU. Characterisation of HLA-DR antigen in patients type 1 diabetes mellitus in patient attending a tertairy hospital in Enugu, south-east Nigeria. ACADEMIC JOURNAL. 2023.
39. Okoroiwu IL, Obeagu EI, Obeagu GU, Chikezie CC, Ezema GO. The prevalence of selected autoimmune diseases. Int. J. Adv. Multidiscip. Res. 2016;3(3):9-14.
40. Nwakuilite A, Nwanjo HU, Nwosu DC, Obeagu EI. EVALUATION OF ENZYME ANTIOXIDANTS IN STREPTOZOCIN INDUCED DIABETIC RATS TREATED WITH MORINGA OLEIFERA LEAF POWDER. European Journal of Biomedical. 2020;7(11):285-288.
41. Nwosu DC, Nwanjo HU, Opara AU, Ofor IB, Obeagu EI, Ugwu GU, Ojiegbe GC, Nnorom RM, Nwokike GI, Okpara KE, Ochei KC. EVALUATION OF C-REACTIVE PROTEIN, SELENIUM AND GLYCOSYLATED HAEMOGLOBIN LEVELS IN DIABETIC PATIENTS ATTENDING METABOLIC CLINIC IN THE FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. **World Journal of Pharmacy and Pharmaceutical Sciences, 2015; 4 (3):141-152.** https://www.academia.edu/download/38320132/NWOSU_EMMA_9.pdf.
42. Nwakuilite A, Nwanjo HU, Nwosu DC, Obeagu EI. EVALUATION OF KIDNEY INJURY MOLECULE-1, CYSTATIN C, AND SERUM ELECTROLYTES IN STREPTOZOCIN INDUCED DIABETIC RATS TREATED WITH MORINGA OLEIFERA LEAF POWDER. Education. 2002.
43. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023 Jun 10;6(2):10-13.
44. Obeagu EI, Mohamod AH. An update on Iron deficiency anaemia among children with congenital heart disease. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(4):45-48.
45. Edward U, Osuorji VC, Nnodim J, Obeagu EI. Evaluationof Trace Elements in Sickle Cell Anaemia Patients Attending Imo State Specialist Hospital, Owerri. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035. 2022 Mar 4;2(1):218-234.

Citation: Obeagu EI, Elamin EAI Obeagu GU. Balancing Act: Glycemic Control and Hematological Considerations in Sickle Cell Diabetes. *Elite Journal of Haematology, 2024; 2(3):* 136-147

46. Umar MI, Aliyu F, Abdullahi MI, Aliyu MN, Isyaku I, Aisha BB, Sadiq RU, Shariff MI, Obeagu EI. Assessment Of Factors Precipitating Sickle Cell Crises Among Under 5-Years Children Attending Sickle Cell Clinic Of Murtala Muhammad Specialist Hospital, Kano. blood.;11:16.
47. Obeagu EI. Vaso-occlusion and adhesion molecules in sickle cells disease. Int J Curr Res Med Sci. 2018;4(11):33-35.
48. Ifeanyi OE, Stella EI, Favour AA. Antioxidants In The Management of Sickle Cell Anaemia. Int J Hematol Blood Disord (Internet) 2018 (cited 2021 Mar 4); 3. Available from: https://symbiosisonlinepublishing. com/hematology/hema tology25. php. 2018 Sep.
49. Buhari HA, Ahmad AS, Obeagu EI. Current Advances in the Diagnosis and Treatment of Sickle Cell Anaemia. APPLIED SCIENCES (NIJBAS). 2023;4(1).
50. Nnodim J, Uche U, Ifeoma U, Chidozie N, Ifeanyi O, Oluchi AA. Hepcidin and erythropoietin level in sickle cell disease. British Journal of Medicine and Medical Research. 2015;8(3):261-5.
51. Obeagu EI. BURDEN OF CHRONIC OSTEOMYLITIS: REVIEW OF ASSOCIATIED FACTORS. Madonna University journal of Medicine and Health Sciences. 2023;3(1):1-6.
52. Aloh GS, Obeagu EI, Okoroiwu IL, Odo CE, Chibunna OM, Kanu SN, Elemchukwu Q, Okpara KE, Ugwu GU. Antioxidant-Mediated Heinz Bodies Levels of Sickle Erythrocytes under Drug-Induced Oxidative Stress. European Journal of Biomedical and Pharmaceutical sciences. 2015;2(1):502-507.
53. Obeagu EI, Bot YS, Opoku D, Obeagu GU, Hassan AO. Sickle Cell Anaemia: Current Burden in Africa. International Journal of Innovative and Applied Research. 2023;11(2):12-14.
54. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023 Jun 10; 6 (2): 10-13.
55. Obeagu EI, Ogbuabor BN, Ikechukwu OA, Chude CN. Haematological parameters among sickle cell anemia patients' state and haemoglobin genotype AA individuals at Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. International Journal of Current Microbiology and Applied Sciences. 2014;3(3):1000-1005.
56. Ifeanyi OE, Nwakaego OB, Angela IO, Nwakaego CC. Haematological parameters among sickle cell anaemia... Emmanuel Ifeanyi1, et al. pdf• Obeagu. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1000-1005.
57. Obeagu EI, Abdirahman BF, Bunu UO, Obeagu GU. Obsterics characteristics that effect the newborn outcomes. Int. J. Adv. Res. Biol. Sci. 2023;10(3):134-143.
58. Obeagu EI, Opoku D, Obeagu GU. Burden of nutritional anaemia in Africa: A Review. Int. J. Adv. Res. Biol. Sci. 2023;10(2):160-163.
59. Ifeanyi E. Erythropoietin (Epo) Level in Sickle Cell Anaemia (HbSS) With Falciparum Malaria Infection in University Health Services, Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. PARIPEX - INDIAN JOURNAL OF RESEARCH, 2015; 4(6): 258-259

Citation: Obeagu EI, Elamin EAI Obeagu GU. Balancing Act: Glycemic Control and Hematological Considerations in Sickle Cell Diabetes. *Elite Journal of Haematology, 2024; 2(3):* 136-147

60. Ifeanyi OE, Nwakaego OB, Angela IO, Nwakaego CC. Haematological parameters among sickle cell anaemia patients in steady state and haemoglobin genotype AA individuals at Michael Okpara, University of Agriculture, Umudike, Abia State, Nigeria. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1000-1005.
61. Ifeanyi OE, Stanley MC, Nwakaego OB. Comparative analysis of some haematological parameters in sickle cell patients in steady and crisis state at michael okpara University of agriculture, Umudike, Abia state, Nigeria. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1046-1050.
62. Ifeanyi EO, Uzoma GO. Malaria and The Sickle Cell Trait: Conferring Selective Protective Advantage to Malaria. J Clin Med Res. 2020; 2:1-4.
63. Ifeanyi OE. Gestational Diabetes: Haematological Perspective. **South Asian Research Journal of Applied Medical Sciences, 1 (2):41-42. DOI: 10.36346/SARJAMS.2019.v01i02.003** https://sarpublication.com/media/articles/SARJAMS_12_41-42.pdf.
64. Ogbu IS, Odeh EJ, Ifeanyichukwu OE, Ogbu C, Ude UA, Obeagu EI. Prevalence of prediabetes among first degree relatives of type 2 diabetes individuals in Abakaliki, Ebonyi State Nigeria. Academic Journal of Health Sciences: Medicina Balear. 2023;38(2):85-88. https://dialnet.unirioja.es/servlet/articulo?codigo=8845439.
65. Ifeanyi OE. An update on Diabetes Mellitus. Int. J. Curr. Res. Med. Sci. 2018;4(6):71-81.DOI: 10.22192/ijcrms.2018.04.06.012 links/5b3b97a04585150d23f63e76/An-update-on-Diabetes-Mellitus.pdf.
66. Vona R, Sposi NM, Mattia L, Gambardella L, Straface E, Pietraforte D. Sickle cell disease: role of oxidative stress and antioxidant therapy. Antioxidants. 2021;10(2):296.
67. Wang Q, Zennadi R. The role of RBC oxidative stress in sickle cell disease: from the molecular basis to pathologic implications. Antioxidants. 2021;10(10):1608.
68. Soliman AT, De Sanctis V, Yassin M, Alshurafa A, Ata F, Nashwan A. Blood transfusion and iron overload in patients with Sickle Cell Disease (SCD): Personal experience and a short update of diabetes mellitus occurrence. Acta Bio Medica: Atenei Parmensis. 2022;93(4).
69. Gordon DK, Hussain M, Kumar P, Khan S, Khan S. The sickle effect: the silent titan affecting glycated hemoglobin reliability. Cureus. 2020;12(8).
70. Kaur R, Kaur M, Singh J. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies. Cardiovascular diabetology. 2018; 17:1-7.
71. Obeagu EI, Obeagu GU. Synergistic Care Approaches: Integrating Diabetes and Sickle Cell Anemia Management. Elite Journal of Scientific Research and Review. 2024;2(1):51-64.
72. Obeagu EI, Obeagu GU. Dual Management: Diabetes and Sickle Cell Anemia in Patient Care. Elite Journal of Medicine. 2024;2(1):47-56.

Citation: Obeagu EI, Elamin EAI Obeagu GU. Balancing Act: Glycemic Control and Hematological Considerations in Sickle Cell Diabetes. *Elite Journal of Haematology, 2024; 2(3):* 136-147

73. Ballas SK, Kesen MR, Goldberg MF, Lutty GA, Dampier C, Osunkwo I, Wang WC, Hoppe C, Hagar W, Darbari DS, Malik P. Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management. The Scientific World Journal. 2012.

Citation: Obeagu EI, Elamin EAI Obeagu GU. Balancing Act: Glycemic Control and Hematological Considerations in Sickle Cell Diabetes. *Elite Journal of Haematology, 2024; 2(3):* 136-147